Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants

Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants

Misfolding and aggregation of the neuronal protein alpha-synuclein (aSyn) has been identified as a hallmark of Parkinson’s disease (PD) pathology and other synucleinopathies. Preventing formation of intracellular aSyn accumulations constitutes a therapeutic strategy against disease development. We r...

Full description

Saved in:

Bibliographic Details
Main Authors:	Linnea Charlotta Hjelm, Wojciech Paslawski, Christofer Lendel, Siri Flemming Svedmark, Per Svenningsson, Stefan Ståhl, Hanna Lindberg, John Löfblom
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Immunology
Subjects:	affibody molecule alpha-synuclein directed evolution Parkinson’s disease phage display sequestrin
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1574755/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mapping of an epitope of ErbB-2 for recognizing by monoclonal antibody 4B8 using phage display technolog
by: M. B. Borgoyakova, et al.
Published: (2016-02-01)

Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development
by: Narmin Nazeri, et al.
Published: (2025-07-01)

Construction and application of a large capacity VNAR library from the whitespotted bamboo shark (Chiloscyllium playgiosum)
by: Hao Li, et al.
Published: (2025-04-01)

α-synuclein fibrils per se but not α-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons
by: Plamena R. Angelova, et al.
Published: (2025-10-01)

Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation
by: Mateusz Putyrski, et al.
Published: (2025-12-01)

Large‐scale phosphomimetic screening identifies phospho‐modulated motif‐based protein interactions
by: Johanna Kliche, et al.
Published: (2023-05-01)

Toward alpha‐synuclein seed amplification assay in clinical practice
by: Mathieu Verdurand, et al.
Published: (2025-01-01)

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)

Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
by: Hallie H. Dolin, et al.
Published: (2025-07-01)

Effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability
by: Elena A. Ostrakhovitch, et al.
Published: (2025-05-01)

Parkinson’s Disease: A Narrative of the Evolving Understanding of the Role of α-Synuclein in Screening
by: Alan D. Kaye, et al.
Published: (2024-11-01)

Seeding and transgenic overexpression of alpha‐synuclein triggers dendritic spine pathology in the neocortex
by: Sonja Blumenstock, et al.
Published: (2017-03-01)

Affibodies as valuable tool to prevent β2m aggregation under lysosomal-like conditions
by: Cristina Visentin, et al.
Published: (2025-06-01)

THE LEVEL OF Α-SYNUCLEIN IN THE PLASMA AS A BIOMARKER OF PAIN IN PARKINSON'S DISEASE TAKING INTO ACCOUNT THE MOTOR SUBTYPES
by: K.A. Tarianyk
Published: (2024-07-01)

Dityrosine-Mediated Inhibition of α-Synuclein Fibrillation Using Photocatalytic Nanoparticles
by: Sonali Jena, et al.
Published: (2024-04-01)

Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning
by: Tomoyuki Ito, et al.
Published: (2023-12-01)

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen
by: Louis Plüss, et al.
Published: (2023-12-01)

Pathological α-synuclein elicits granulovacuolar degeneration independent of tau
by: Dylan J. Dues, et al.
Published: (2025-06-01)

Photochemically synthesized gold nanoparticles conjugated with Boswellic acid inhibit alpha synuclein aggregation and delay fibrillation kinetics
by: Masoumeh Gharb, et al.
Published: (2025-07-01)

Nanotherapeutic Approaches of Interleukin‐3 to Clear the α‐Synuclein Pathology in Mouse Models of Parkinson's Disease
by: Wenlong Zhang, et al.
Published: (2024-11-01)

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species
by: Mª Salomé Sirerol-Piquer, et al.
Published: (2025-03-01)

Experimental and computational insights into the therapeutic mechanisms of resveratrol in a Drosophila α-synuclein model of Parkinson’s disease
by: Amos Olalekan Abolaji, et al.
Published: (2025-05-01)

SH3 interactome conserves general function over specific form
by: Xiaofeng Xin, et al.
Published: (2013-04-01)

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties
by: Abdullah Elsayed, et al.
Published: (2023-12-01)

Trans-sodium crocetinate ameliorates Parkinson-like disease caused by bisphenol A through inhibition of apoptosis and reduction of α-synuclein in rats
by: Majid Keshavarzi, et al.
Published: (2025-02-01)

Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2
by: Federica Albanese, et al.
Published: (2025-03-01)

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
by: Martin Schuler, et al.
Published: (2025-04-01)

Multivalent design of the monoclonal SynO2 antibody improves binding strength to soluble α-Synuclein aggregates
by: Inga Petersen, et al.
Published: (2023-12-01)

Discovery of <i>N</i>-(6-Methoxypyridin-3-yl)quinoline-2-amine Derivatives for Imaging Aggregated α-Synuclein in Parkinson’s Disease with Positron Emission Tomography
by: Haiyang Zhao, et al.
Published: (2025-07-01)

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein
by: Jingfeng Liang, et al.
Published: (2025-08-01)

High-Performance Genome Annotation for a Safer and Faster-Developing Phage Therapy
by: Antoine Culot, et al.
Published: (2025-02-01)

Identification of novel human IgE-binding peptides from a phage display library for total IgE detection
by: Sudtida Kaew-amdee, et al.
Published: (2025-07-01)

Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential
by: Chaowen Shi, et al.
Published: (2025-07-01)

Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide
by: Prakash Lingasamy, et al.
Published: (2025-08-01)

Therapeutic Optimization of <i>Pseudomonas aeruginosa</i> Phages: From Isolation to Directed Evolution
by: Sara Bolognini, et al.
Published: (2025-06-01)

Optimizing phage therapy with artificial intelligence: a perspective
by: Michael B. Doud, et al.
Published: (2025-05-01)

GDNF attenuates a-synuclein aggregation-induced damage to VTA-NAc dopaminergic transmission and alleviates depression-like behaviors in mice
by: Jing Chen, et al.
Published: (2025-08-01)

Biological foundations of successful bacteriophage therapy
by: Carola Venturini, et al.
Published: (2022-05-01)

Phage DisCo: targeted discovery of bacteriophages by co-culture
by: Eleanor A. Rand, et al.
Published: (2025-06-01)

Biological Characteristics and Genomic Analysis of <i>Acinetobacter nosocomialis</i> Lytic Phage XC1
by: Chuhan Wang, et al.
Published: (2025-05-01)